Mybacguard (SCB-211) / SciBac - LARVOL DELTA

[VIRTUAL] USE OF A NOVEL LIVE BIOTHERAPEUTIC IN THE LUNG TO PREVENT AND TREAT PROGRESSIVE MYCOBACTERIUM ABSCESSUS INFECTIONS (NACFC 2020) - "These preliminary studies suggest SCB-211 is well tolerated in the lungs and may provide an alternative treatment to stop the progression of Mycobacterium abscessus infections. This live biotherapeutic will be developed for local delivery to the lungs via intranasal drops as an alternative to antibiotic therapy. The development of SCB-211 for localized treatment of CF-associated NTM infections is a novel strategy to combat a serious unmet need in CF patients and may result in fewer side effects and more positive therapeutic outcomes."

Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Nontuberculous Mycobacterial Disease • Respiratory Diseases